APDN
APDN
Applied DNA Sciences, Inc. • NASDAQ
$5.62 ▲ 31.62% (+1.35)
Market Cap $2.92 M
52w High $319.95
52w Low $2.13
Dividend Yield 0%
P/E -0.09838935574229692
Volume 2.65M
Outstanding Shares 1.29M
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $304.393K ▼ | $3.699M ▼ | $-3.945M ▲ | -1.296K% ▲ | $-34 ▼ | $-3.616M ▼ |
| Q2-2025 | $983.374K ▼ | $3.833M ▲ | $-27.224M ▼ | -2.768K% ▼ | $-15.35 ▼ | $-3.462M ▼ |
| Q1-2025 | $1.197M ▲ | $3.648M ▲ | $-2.639M ▲ | -220.573% ▲ | $-0.56 ▼ | $-2.905M ▲ |
| Q4-2024 | $813.107K ▲ | $3.516M ▼ | $-3.297M ▼ | -405.45% ▼ | $-0.19 ▼ | $-3.194M ▲ |
| Q3-2024 | $797.519K | $3.592M | $1.88M | 235.705% | $0.47 | $-3.213M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $4.728M ▼ | $9.935M ▼ | $2.947M ▲ | $7.263M ▼ |
| Q2-2025 | $6.823M ▼ | $13.036M ▼ | $2.811M ▼ | $10.46M ▼ |
| Q1-2025 | $9.294M ▲ | $15.971M ▲ | $3.421M ▼ | $12.753M ▲ |
| Q4-2024 | $6.431M ▼ | $12.789M ▼ | $3.821M ▼ | $9.143M ▼ |
| Q3-2024 | $10.442M | $16.69M | $4.456M | $12.392M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.581M ▼ | $-2.816M ▲ | $10.077K ▲ | $723.056K ▼ | $-2.083M ▲ | $-2.827M ▲ |
| Q2-2025 | $-3.336M ▼ | $-3.185M ▲ | $-185.319K ▼ | $899.249K ▼ | $-2.471M ▼ | $-3.37M ▲ |
| Q1-2025 | $-2.669M ▲ | $-3.326M ▼ | $-116.879K ▲ | $6.306M ▲ | $2.863M ▲ | $-3.443M ▲ |
| Q4-2024 | $-3.297M ▼ | $-3.249M ▲ | $-371.25K ▼ | $-390.721K ▼ | $-4.011M ▼ | $-3.62M ▼ |
| Q3-2024 | $1.88M | $-3.495M | $-21.826K | $10.809M | $7.292M | $-3.516M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Large Scale DNA Production | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Research and Development Services OverTime | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Supply Chain | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Asset Marking | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Clinical Laboratory Testing Services OverTime | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
 Clinical Laboratory Testing Services PointinTime | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
Market Cap $2.92 M
52w High $319.95
52w Low $2.13
Dividend Yield 0%
P/E -0.09838935574229692
Volume 2.65M
Outstanding Shares 1.29M
About Applied DNA Sciences, Inc.
https://www.adnas.comApplied DNA Sciences, Inc. develops and markets DNA-based technology solutions for use in the nucleic acid-based in vitro diagnostics and preclinical nucleic-acid based drug development and manufacturing markets; and for supply chain security, anti-counterfeiting, and anti-theft technology purposes.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $304.393K ▼ | $3.699M ▼ | $-3.945M ▲ | -1.296K% ▲ | $-34 ▼ | $-3.616M ▼ |
| Q2-2025 | $983.374K ▼ | $3.833M ▲ | $-27.224M ▼ | -2.768K% ▼ | $-15.35 ▼ | $-3.462M ▼ |
| Q1-2025 | $1.197M ▲ | $3.648M ▲ | $-2.639M ▲ | -220.573% ▲ | $-0.56 ▼ | $-2.905M ▲ |
| Q4-2024 | $813.107K ▲ | $3.516M ▼ | $-3.297M ▼ | -405.45% ▼ | $-0.19 ▼ | $-3.194M ▲ |
| Q3-2024 | $797.519K | $3.592M | $1.88M | 235.705% | $0.47 | $-3.213M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $4.728M ▼ | $9.935M ▼ | $2.947M ▲ | $7.263M ▼ |
| Q2-2025 | $6.823M ▼ | $13.036M ▼ | $2.811M ▼ | $10.46M ▼ |
| Q1-2025 | $9.294M ▲ | $15.971M ▲ | $3.421M ▼ | $12.753M ▲ |
| Q4-2024 | $6.431M ▼ | $12.789M ▼ | $3.821M ▼ | $9.143M ▼ |
| Q3-2024 | $10.442M | $16.69M | $4.456M | $12.392M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-3.581M ▼ | $-2.816M ▲ | $10.077K ▲ | $723.056K ▼ | $-2.083M ▲ | $-2.827M ▲ |
| Q2-2025 | $-3.336M ▼ | $-3.185M ▲ | $-185.319K ▼ | $899.249K ▼ | $-2.471M ▼ | $-3.37M ▲ |
| Q1-2025 | $-2.669M ▲ | $-3.326M ▼ | $-116.879K ▲ | $6.306M ▲ | $2.863M ▲ | $-3.443M ▲ |
| Q4-2024 | $-3.297M ▼ | $-3.249M ▲ | $-371.25K ▼ | $-390.721K ▼ | $-4.011M ▼ | $-3.62M ▼ |
| Q3-2024 | $1.88M | $-3.495M | $-21.826K | $10.809M | $7.292M | $-3.516M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
| Large Scale DNA Production | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
| Research and Development Services OverTime | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
| Supply Chain | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
| Asset Marking | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
| Clinical Laboratory Testing Services OverTime | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
| Clinical Laboratory Testing Services PointinTime | $0 ▲ | $0 ▲ | $0 ▲ | $0 ▲ |
CEO
James A. Hayward Sc.D.
Compensation Summary
(Year 2024)
Salary $0
Bonus $0
Stock Awards $0
Option Awards $0
Incentive Plan Pay $0
All Other Compensation $0
Outstanding Value $0
Total Compensation (Unknown At The Moment)
CEO
James A. Hayward Sc.D.
Compensation Summary
(Year 2024)
Salary $0
Bonus $0
Stock Awards $0
Option Awards $0
Incentive Plan Pay $0
All Other Compensation $0
Outstanding Value $0
Total Compensation (Unknown At The Moment)
Industry Medical - Diagnostics & Research
Sector Healthcare
Went public July 15, 2003
Method of going public IPO
Full time employees 46
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2025-06-02 | Reverse | 1:15 |
| 2025-03-14 | Reverse | 1:50 |
| 2024-04-25 | Reverse | 1:20 |
| 2019-11-01 | Reverse | 1:40 |
| 2014-10-29 | Reverse | 1:60 |
Price Target
Target High $1.5
Target Low $1.5
Target Median $1.5
Target Consensus $1.5
Institutional Ownership
COWEN PRIME ADVISORS LLC
98.301K Shares
$552.452K
PROVENCE WEALTH MANAGEMENT GROUP
2K Shares
$11.24K
ADVISOR GROUP, INC.
52 Shares
$292.24
LADENBURG THALMANN FINANCIAL SERVICES INC.
1 Shares
$5.62
Summary
% Of Shares Owned 7.77%
Total Number Of Holders 4
Only Showing The Top 4
Sectors Peers
| Peer | Price | Market Cap |
|---|---|---|
 QTTB | $2.16 | $26.35M |